SBIR TOPIC 415: Design and Construction of a Novel Electron Brachytherapy Source Driven by a Laser Plasma Accelerator

A.背景资料 这项提议的长期目标是推进激光等离子体治疗癌症。 加速器物理学在LBNL取得突破，将建造一台微型电子加速器作为可变X射线 临床相关剂量率为~0.7Gymin，能量在0.25-5 MeV之间。 这种电子粒子近距离治疗源是由商业激光系统提供动力的，正在运行 至1000赫兹，平均功率为7W。激光驱动器的灵活性允许治疗 无放射性同位素运行和脉冲基础上的可变x射线能量。这会带来额外的好处 治疗计划过程的自由度，从而为临床医生提供了 提高剂量投放。减少了对附近健康组织和关键结构的不必要剂量。 这项提议汇集了一支世界级的团队：LBNL在激光等离子体加速器和光学 基于光纤的输送系统，Woodtoga将该技术转化为临床相关产品 拥有粘合和微型X射线设备制造方面的专业知识，以及瓦里安医疗系统公司 商业合作伙伴。将该技术与临床实践、治疗计划相结合，形成 放射肿瘤学平台改变了近距离放射治疗领域。

A. Background Information The long-term objective of this proposal is to advance the treatment of cancer using laser plasma accelerator physics breakthroughs at LBNL to build a miniature electron accelerator as a variable Xrays source with clinically relevant dose-rates of ~0.7 Gy/min and energies between 0.25 – 5 MeV. This electronic particle brachytherapy source is powered by a commercial, laser system, operating up to 1000 Hz and 7 W of average power. The flexibility of the laser driver allows treatment with radioisotope-free operation and variable x-ray energy on a pulse-by-pulse basis. This confers extra degrees of freedom for the treatment planning process thus providing the clinician the ability to improve the dose delivery. Unwanted dose to nearby healthy tissue and critical structures is reduced. This proposal brings a world-class team together: LBNL in laser plasma accelerators and optical fiber-based delivery systems, Woodtoga to translate the technology into clinically relevant products with expertise in bonding and the creation of miniature X-ray devices, and Varian Medical Systems as the commercial partner. Integrating the technology with clinical practice, treatment planning, into a radiation oncology platform transforming the field of brachytherapy.